Log in
CVE:SQD

SQI Diagnostics Stock Forecast, Price & News

C$0.27
0.00 (0.00 %)
(As of 10/23/2020 03:59 PM ET)
Add
Compare
Today's Range
C$0.27
Now: C$0.27▼
C$0.28
50-Day Range
C$0.22
MA: C$0.26▼
C$0.27
52-Week Range
C$0.06
Now: C$0.27▼
C$0.29
Volume750,000 shs
Average Volume244,670 shs
Market CapitalizationC$82.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange CVE
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolCVE:SQD
Previous Symbol
CUSIPN/A
CIKN/A
Websqidiagnostics.com
Phone+1-416-6749500
Employees42

Debt

Debt-to-Equity Ratio142.70
Current Ratio3.81
Quick Ratio3.43

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesC$1.41 million
Price / Sales58.47
Cash FlowC$0.01 per share
Price / Cash Flow19.29
Book ValueC$0.01 per share
Price / Book22.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares305,797,000
Market CapC$82.57 million
Next Earnings Date12/9/2020 (Estimated)
OptionableNot Optionable
C$0.27
0.00 (0.00 %)
(As of 10/23/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SQD News and Ratings via Email

Sign-up to receive the latest news and ratings for SQD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SQI Diagnostics (CVE:SQD) Frequently Asked Questions

How has SQI Diagnostics' stock price been impacted by COVID-19 (Coronavirus)?

SQI Diagnostics' stock was trading at C$0.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SQD shares have increased by 260.0% and is now trading at C$0.27.
View which stocks have been most impacted by COVID-19.

When is SQI Diagnostics' next earnings date?

SQI Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, December 9th 2020.
View our earnings forecast for SQI Diagnostics.

How were SQI Diagnostics' earnings last quarter?

SQI Diagnostics Inc. (CVE:SQD) announced its earnings results on Thursday, August, 27th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $0.30 million during the quarter.
View SQI Diagnostics' earnings history.

Who are some of SQI Diagnostics' key competitors?

Some companies that are related to SQI Diagnostics include Exagen (XGN), Yourgene Health Plc (YGEN.L) (YGEN), Senseonics (SENS), Oncimmune (ONC), Palatin Technologies (PTN), LexaGene Holdings Inc. (LXG.V) (LXG), genedrive plc (GDR.L) (GDR), Sernova (SVA), GeneNews (GEN), Cambridge Cognition Holdings Plc (COG.L) (COG), LED Medical Diagnostics (LMD), Deepmatter Group (DMTR), VentriPoint Diagnostics (VPT), Imaging Dynamics (IDL) and 3D Signatures (DXD).
View all competitors.

What other stocks do shareholders of SQI Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SQI Diagnostics investors own include Cigna (CI), Global Payments (GPN), Alarm.com (ALRM), Brookfield Asset Management (BAM.A), Baxter International (BAX), Becton, Dickinson and (BDX), Charter Communications (CHTR), Costco Wholesale (COST), Canadian Tire (CTC.A) and CytRx (CYTR).

Who are SQI Diagnostics' key executives?

SQI Diagnostics' management team includes the following people:
  • Mr. Andrew Morris, CEO, Pres & Director (Age 53)
  • Ms. Patricia Lie CPA, CA, VP of Fin. & Admin.
  • Dr. Eric Brouwer, Chief Scientific Officer
  • Dr. Peter Lea Ph.D., Founder (Age 74)
  • Mr. Russell Peloquin, VP of Global Commercial Operations

What is SQI Diagnostics' stock symbol?

SQI Diagnostics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SQD."

How do I buy shares of SQI Diagnostics?

Shares of SQD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is SQI Diagnostics' stock price today?

One share of SQD stock can currently be purchased for approximately C$0.27.

How big of a company is SQI Diagnostics?

SQI Diagnostics has a market capitalization of C$82.57 million and generates C$1.41 million in revenue each year. SQI Diagnostics employs 42 workers across the globe.

What is SQI Diagnostics' official website?

The official website for SQI Diagnostics is sqidiagnostics.com.

How can I contact SQI Diagnostics?

SQI Diagnostics' mailing address is 36 Meteor Dr, ETOBICOKE, ON M9W 1A4, Canada. The company can be reached via phone at +1-416-6749500.

This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.